Nevadensin
(Synonyms: 石吊兰素) 目录号 : GC38824
Nevadensin 是一种天然存在的人羧酸酯酶1 (hCE1) 选择性抑制剂，IC50 值为 2.64 μM。Nevadensin 具有抗结核分枝杆菌、镇咳、抗炎、抗高血压等多种药理作用。
Cas No.:10176-66-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 (hCE1) with an IC50 of 2.64 μM. Nevadensin has a variety of pharmacological effects such as anti-mycobacterium tuberculosis activities, antitussive, anti-inflammatory and anti-hypertensive[1][2].
| Cas No. | 10176-66-6 | SDF | |
| 别名 | 石吊兰素 | ||
| Canonical SMILES | O=C1C=C(C2=CC=C(OC)C=C2)OC3=C(OC)C(O)=C(OC)C(O)=C13 | ||
| 分子式 | C18H16O7 | 分子量 | 344.32 |
| 溶解度 | DMSO : 14.71 mg/mL (42.72 mM; Need ultrasonic) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Potential Nevadensin from Ocimum basilicum as Antibacterial Agent against Streptococcus mutans: In Vitro and In Silico Studies
Comb Chem High Throughput Screen 2022 Sep 30.PMID:36200248DOI:10.2174/1386207325666220930122813.
Background: Streptococcus mutans is one of the bacteria which contributes to biofilm formation and causes dental caries. The inhibition of SrtA, gbpC, and Ag I/II is a promising target to be developed as an antibacterial. Ocimum bacilicum is known to have antibacterial activity. Aim and objective: The aim of this study is to evaluate the potential Nevadensin as antibacterial against S. mutans. Methods: Antibacterial analysis was carried out by disc diffusion and micro-dilution methods and the in-silico study was performed with ligand-protein docking. Results: The result showed that the MIC and MBC values of Nevadensin are 900 and 7200 µg/mL, respectively. The binding energy of Nevadensin to SrtA, gbpC, and Ag I/II were -4.53, 8.37, -6.12 kcal/mol, respectively. Conclusion: Nevadensin shows moderate activity as an antibacterial against S. mutans. Meanwhile, in silico studies showed it has the same binding strength as chlorhexidine in inhibiting SrtA, whereas to gbpC and Ag I/II, it has a weaker binding affinity. Therefore, Nevadensin has the potential as natural antibacterial against S. mutans by inhibiting SrtA.
Metabolic conjugation reduces in vitro toxicity of the flavonoid Nevadensin
Food Chem Toxicol 2022 Jun;164:113006.PMID:35436549DOI:10.1016/j.fct.2022.113006.
The present study focuses on the association between metabolic capacity and toxicity of the natural occurring flavonoid Nevadensin in vitro. Human colon (HT29), liver (HepG2) and bone marrow (KG1) carcinoma cells were used and strong cell line dependent differences in toxic effect strength were found. HepG2 and KG1 cells were more sensitive against Nevadensin treatment in comparison to HT29 cells. High resolution mass spectrometry experiments showed that Nevadensin is rapidly glucuronidated in HT29 cells, whereas KG1 cells do not metabolize Nevadensin, thus glucuronidation was supposed to be a crucial metabolic pathway in vitro. To proof this suggestion, Nevadensin glucuronides were isolated from pig liver microsomes und structurally elucidated via NMR spectroscopy. In HepG2 cells a cellular enrichment of Nevadensin itself as well as nevadensin-7-O-glucuronide was determined by tandem mass spectrometry. A proteomic screening of uridine 5'-diphospho (UDP)-glucuronosyltransferase (UGT) in HT29 and HepG2 cells provided first hints that the isoforms UGT1A6 and UGT1A1 are responsible for Nevadensin glucuronidation. Additionally, Nevadensin was found to be a potent SULT inhibitor in HepG2 cells. In sum, the present study clearly illustrates the importance of obtaining detailed information about metabolic competence of cell lines which should be considered in the evaluation of toxic endpoints.
Prediction Mechanism of Nevadensin as Antibacterial Agent against S. sanguinis: In vitro and In silico Studies
Comb Chem High Throughput Screen 2022;25(9):1488-1497.PMID:34238151DOI:10.2174/1386207324666210707104440.
Background: Streptococcus sanguinis can contribute to tooth demineralization, which can lead to dental caries. Antibiotics used indefinitely to treat dental caries can lead to bacterial resistance. Discovering new antibacterial agents from natural products, like Ocimum basilicum, will help combat antibiotic resistance. In silico analysis (molecular docking) can help determine the lead compound by studying the molecular interaction between the drug and the target receptor (MurA enzyme and DNA gyrase). It is a potential candidate for antibacterial drug development. Objectives: The research objective is to isolate the secondary metabolite of O. basilicum extract that exhibits activity against S. sanguinis through in vitro and in silico analysis. Methods: n-Hexane extract of O. basilicum was purified by combining column chromatography with bioactivity-guided fractionation. The in vitro antibacterial activity against S. sanguinis was determined using the disc diffusion and microdilution method, while molecular docking simulation of Nevadensin (1) with MurA enzyme and DNA gyrase was performed by using PyRx 0.8 program. Results: Nevadensin from O. basilicum was successfully isolated and characterized by spectroscopic methods. This compound showed antibacterial activity against S. sanguinis with MIC and MBC values of 3750 and 15000 μg/mL, respectively. In silico analysis showed that the binding affinity to MurA was -8.5 Kcal/mol, and the binding affinity to DNA gyrase was -6.7 Kcal/mol. The binding of nevadensin-MurA is greater than fosfomycin-MurA. Otherwise, Nevadensin-DNA gyrase has a weaker binding affinity than fluoroquinolone-DNA gyrase and chlorhexidine-DNA gyrase. Conclusion: Nevadensin showed potential as a new natural antibacterial agent by inhibiting the MurA enzyme rather than DNA gyrase.
Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1
Int J Biol Macromol 2018 Dec;120(Pt B):1944-1954.PMID:30268757DOI:10.1016/j.ijbiomac.2018.09.178.
Human carboxylesterase 1 (hCE1) is a key enzyme responsible for the hydrolysis of a wide range of endogenous and xenobiotic esters, but the highly selective inhibitors against hCE1 are rarely reported. This study aimed to assess the inhibitory effects of natural flavonoids against hCE1 and to find potential specific hCE1 inhibitors. To this end, fifty-eight natural flavonoids were collected and their inhibitory effects against both hCE1 and hCE2 were assayed. Among all tested compounds, Nevadensin, an abundant natural constitute from Lysionotus pauciflorus Maxim., displayed the best combination of inhibition potency and selectivity towards hCE1. The inhibition mechanism of Nevadensin on hCE1 was further investigated using two site-specific hCE1 substrates including D-luciferin methyl ester (DME) and 2‑(2‑benzoyloxy‑3‑methoxyphenyl)benzothiazole (BMBT). Furthermore, docking simulations demonstrated that the binding area of Nevadensin on hCE1 was highly overlapped with that of DME but was far away from that of BMBT, which was highly consistent with the inhibition modes of Nevadensin. These findings found a natural occurring specific inhibitor of hCE1, which could be served as a lead compound for the development of novel hCE1 inhibitor with improved properties, and also hold great promise for investigating hCE1-ligand interactions.
Metabolism profiling of Nevadensin in vitro and in vivo by UHPLC-Q-TOF-MS/MS
J Chromatogr B Analyt Technol Biomed Life Sci 2018 May 1;1084:69-79.PMID:29573625DOI:10.1016/j.jchromb.2018.03.032.
Nevadensin is major constituents of Lysionotus pauciflorus Maxim. (Chinese name: Shidiaolan), which has a variety of pharmacological effects such as anti-mycobacterium tuberculosis activities, antitussive, anti-inflammatory and anti-hypertensive. In this paper, we investigated the metabolism of Nevadensin in vitro and in vivo. A strategy was firstly developed to identify the metabolites of Nevadensin by using ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS/MS). An on-line data acquisition method a multiple mass defect filter (MMDF) combined with dynamic background subtraction (DBS) was developed to trace all probable metabolites. Furthermore, some assistant tools, such as key fragment ions (KFI), were employed for compound hunting and identification. Based on the proposed method, 23 metabolites were structurally characterized in vivo including 16 phase I and 7 phase II metabolites, and 12 metabolites were detected in vitro containing 10 phase I and 2 phase II metabolites. The results indicated that oxidation, hydrolysis, demethylation, methylation, sulfate conjugation and glucuronide conjugation were main metabolic pathways of Nevadensin. In a word, this study maybe can provide reference and valuable evidence for further investigation of the metabolic mechanism of Nevadensin.